The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship.

Additional Metadata
Persistent URL dx.doi.org/10.1038/s41571-018-0027-x, hdl.handle.net/1765/106296
Journal Nature Reviews Clinical Oncology
Rights no subscription
Citation
Uyl-de Groot, C.A, & Löwenberg, B. (2018). Sustainability and affordability of cancer drugs: a novel pricing model. Nature Reviews Clinical Oncology, 1–2. doi:10.1038/s41571-018-0027-x